Literature DB >> 6799198

Clinical pharmacology of methotrexate.

B A Chabner, R C Donehower, R L Schilsky.   

Abstract

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 6799198

Source DB:  PubMed          Journal:  Cancer Treat Rep        ISSN: 0361-5960


× No keyword cloud information.
  6 in total

1.  The inability of oral leucovorin to elevate CSF 5-methyl-tetrahydrofolate following high dose intravenous methotrexate therapy.

Authors:  J Allen; G Rosen; H Juergens; B Mehta
Journal:  J Neurooncol       Date:  1983       Impact factor: 4.130

2.  Plasma levels of 7-hydroxymethotrexate after high-dose methotrexate treatment.

Authors:  G Milano; A Thyss; N Renee; M Schneider; M Namer; J L Boublil; C M Lalanne
Journal:  Cancer Chemother Pharmacol       Date:  1983       Impact factor: 3.333

3.  Methotrexate-related deaths in patients previously treated with cis-diamminedichloride platinum.

Authors:  N Haim; A Kedar; E Robinson
Journal:  Cancer Chemother Pharmacol       Date:  1984       Impact factor: 3.333

4.  Radioimmunoassay for methotrexate using hydroxyethylmethacrylate hydrogel.

Authors:  K J Tracey; R Mutkoski; J A Lopez; W Franzblau; C Franzblau
Journal:  Cancer Chemother Pharmacol       Date:  1983       Impact factor: 3.333

5.  Comparison of the cytotoxic activities of chemotherapeutic drugs using a human bladder cancer cell line.

Authors:  P J Hepburn; R T Oliver; P A Riley; B T Hill; J R Masters
Journal:  Urol Res       Date:  1985

6.  Circadian pharmacokinetics of methotrexate.

Authors:  B A Robinson; E J Begg; B M Colls; G M Jeffery; J R Sharman
Journal:  Cancer Chemother Pharmacol       Date:  1989       Impact factor: 3.333

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.